This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G12.20 | Special Copayment Reduction: V123 | Coverage period: 5 years |
| B. Synonyms | Familial ALS, FALS, hereditary amyotrophic lateral sclerosis, familial Lou Gehrig's disease |
| C. Adult onset | First onset in adulthood very likely — onset mostly in adulthood, in the 40s–60s; some SOD1 variants may have earlier onset |
| 1. History | Described by Charcot in 1869; research on hereditary ALS took off with the first identification of the SOD1 gene in 1993 |
| 2. Causes | Mutations in ALS-associated genes such as SOD1, C9orf72, FUS and TARDBP |
| 3. Genetics | C9orf72 ~35%, SOD1 ~20%, FUS ~5%, TARDBP ~5%; mostly autosomal dominant |
| 4. General epidemiology | 5–10% of all ALS; prevalence about 0.2–0.4 per 100,000 |
| 5. Pathophysiology | Motor neuron death through protein aggregation, abnormal RNA processing, oxidative stress and impaired axonal transport |
| 6. Symptoms | Progressive muscle weakness, muscle atrophy, bulbar symptoms (dysarthria, dysphagia), respiratory failure |
| 7. Signs | Signs of simultaneous upper and lower motor neuron involvement, fasciculations, increased muscle tone and hyperreflexia |
| 8. Screening | Gene panel testing in high-risk individuals with a family history; family genetic counseling after identification of the proband |
| 9. Diagnosis | El Escorial criteria, gene panel, electromyography, cerebrospinal fluid neurofilament light chain (NfL) |
| 10. Treatment | Riluzole, edaravone; tofersen (ASO) for SOD1-ALS; multidisciplinary supportive care |
| 11. Prognosis | Mean survival after diagnosis 2–5 years; bulbar-onset and C9orf72 forms relatively poor |
| 12. Prevention | Genetic counseling, predictive genetic testing (presymptomatic), preimplantation genetic diagnosis (PGT) |
| 13. References | Rosen DR et al. Nature 1993 and 9 other papers |
Amyotrophic lateral sclerosis (ALS) was established as an independent disease in 1869 when the French neurologist Jean-Martin Charcot first systematically described its clinical characteristic of simultaneous involvement of upper and lower motor neurons. Familial ALS (FALS) is the hereditary form accounting for 5–10% of all ALS, and early family studies relied on clinical observation. The identification in 1993 by Rosen and colleagues of mutations in the SOD1 (Cu/Zn superoxide dismutase 1) gene on chromosome 21 as the first FALS causative gene marked the starting point of ALS molecular genetics. Subsequently, in 2006, TAR DNA-binding protein 43 (TDP-43, TARDBP gene) was identified as the main pathological protein of ALS, and in 2009 mutations in the FUS (Fused in Sarcoma) gene were discovered. In 2011, the GGGGCC hexanucleotide repeat expansion of the C9orf72 gene was identified as the most common single cause of FALS in Europe and North America, revealing the molecular link of the ALS-FTD (frontotemporal dementia) spectrum. In 2023, tofersen (Qalsody), the first gene-specific therapy targeting SOD1-ALS, received FDA approval, opening a new era in which precision medicine approaches entered the clinic.
Familial ALS is a monogenic disease caused by a single gene mutation, but the causative genes are very diverse. To date, more than 30 ALS-related genes have been identified, and the major genes include C9orf72, SOD1, FUS, TARDBP, OPTN, TBK1, UBQLN2 and VCP. The GGGGCC hexanucleotide repeat expansion of the C9orf72 gene accounts for about 35–40% of FALS of European descent and is strongly associated with ALS-FTD overlap syndrome. SOD1 mutations account for about 20% of FALS, with a higher frequency in people of Asian descent, and more than 200 variants have been reported. FUS mutations account for about 5% of FALS and are associated with young adult-onset or juvenile-onset ALS. TARDBP mutations account for about 5% of FALS and are also rarely found in sporadic ALS cases. OPTN (optineurin) and TBK1 mutations are associated with abnormalities of the autophagy–NF-κB pathway. In many FALS families (about 25%), the causative gene remains unidentified to date. A hypothesis has also been proposed that environmental exposures (heavy metals, pesticides, military service, etc.) may promote onset in genetically predisposed individuals.
Most FALS follows an autosomal dominant mode of inheritance, and when one parent is affected, the risk to each child is about 50%. As exceptions, some SOD1 variants (e.g., homozygous D90A) are autosomal recessive, and UBQLN2 mutations show X-linked dominant inheritance. Incomplete penetrance is an important clinical feature, and carriers of the same variant may not develop the disease. The penetrance of the C9orf72 repeat expansion reaches about 50% by age 65 and about 80% by age 80. Variability in age of onset is also marked, ranging from onset in the 30s to the 70s even within the same family. The correlation between repeat expansion length (pathogenic threshold: 30 or more repeats, usually 200–2,000 or more) and clinical phenotype is complex. The SOD1 A4V variant is the most common in North American FALS and is associated with rapid progression (mean survival 1.2 years after diagnosis). The SOD1 D90A variant (Scandinavian Peninsula) is autosomal recessive and shows a relatively mild course. Gene-environment interactions and polygenic risk scores are being studied for their effects on age of onset and phenotype.
Familial ALS accounts for about 5–10% of all ALS patients, and in Western population-based studies the overall prevalence of ALS is about 4–6 per 100,000. Accordingly, the prevalence of FALS is estimated at about 0.2–0.6 per 100,000. Incidence differs by ethnicity: C9orf72-associated FALS is common in people of European descent, while the proportion associated with SOD1 is relatively higher in people of Asian descent (including Korea and Japan). According to domestic epidemiological data, the overall prevalence of ALS is about 3–4 per 100,000, and the proportion of FALS is estimated at about 5–10%, similar to Western countries. Age of onset is generally most common in the 40s–60s, and FALS tends to begin on average about 5–10 years earlier than sporadic ALS. FUS-associated FALS can also occur in young adults under 30. The sex ratio slightly favors males, but in C9orf72-associated forms the male-to-female ratio is more even. Geographic clustering is generally absent in FALS, and vertical transmission within families is characteristic.
The pathophysiology of FALS differs somewhat depending on the causative gene, but in common, multiple molecular pathways are involved that lead to the selective vulnerability and progressive loss of motor neurons. For SOD1 mutations, the main mechanism is gain-of-function toxicity through protein misfolding and formation of toxic aggregates, with involvement of mitochondrial dysfunction, endoplasmic reticulum stress and prion-like propagation. The C9orf72 repeat expansion causes toxicity through two mechanisms: first, RNA foci sequester RNA-binding proteins, causing abnormal RNA processing; and second, dipeptide repeat (DPR) proteins (GA, GR, PA, PR, GP) produced by repeat-associated non-ATG translation (RAN translation) cause impaired nucleocytoplasmic transport and collapse of protein homeostasis. TDP-43 and FUS are RNA-binding proteins that, when mutated, redistribute from the nucleus to the cytoplasm, forming stress granules and pathological aggregates. This TDP-43 pathology is the common final pathological pathway not only of FALS but also of sporadic ALS. Impaired axonal transport, neuromuscular junction dysfunction, glutamate excitotoxicity and neuroinflammation (microglial and astrocyte activation) also accelerate motor neuron death.
The clinical symptoms of FALS are essentially the same as those of sporadic ALS, characterized by simultaneous involvement of both upper and lower motor neurons. The onset pattern is divided into onset in the limbs (limb onset) and onset with bulbar symptoms (bulbar onset). In limb onset, weakness and atrophy usually begin in one hand or foot and then spread to the opposite side and to proximal muscles. Initially, it appears as functional decline such as difficulty gripping, inability to fasten buttons and foot drop. In bulbar onset, dysarthria (slurred speech), dysphagia, and tongue atrophy and fasciculations appear first, and weight loss and the risk of aspiration pneumonia increase. Muscle cramps and fasciculations are very common early symptoms. Respiratory muscle weakness progresses through nocturnal hypoventilation and ultimately to respiratory failure. In C9orf72-associated FALS, cognitive impairment (frontal lobe dysfunction, FTD) may be present, which is clinically important. Pain, sensory abnormalities and autonomic dysfunction are generally absent or mild, and eye movements and bladder function tend to be preserved until the late stage.
On physical examination, the key to diagnosis in FALS is the simultaneous observation of signs of involvement of both upper and lower motor neurons. Lower motor neuron signs include muscle atrophy, fasciculations (including tongue fasciculation), hypotonia, and reduced or absent deep tendon reflexes. Upper motor neuron signs paradoxically include hyperreflexia, the Babinski sign (extensor plantar response), the Hoffmann sign, spasticity and pseudobulbar palsy (pseudobulbar affect: emotional dysregulation). The coexistence of these two types of signs in the same patient is a unique feature of ALS. Tongue atrophy and fasciculations are clear signs of bulbar involvement, and a brisk jaw jerk is also a sign of pseudobulbar palsy. Reduced respiratory function is reflected by decreased seated forced vital capacity (seated FVC) and reduced maximal inspiratory pressure (MIP). Weight loss and muscle wasting become pronounced as the disease progresses. Sensory function is generally normal, and if abnormal, diagnoses other than FALS should be reconsidered. Eye movements are normal until the late stage, but in C9orf72-related ALS, cognitive testing may show frontal lobe dysfunction.
In FALS, presymptomatic genetic testing in individuals whose genetic risk has been identified through family history is the key screening tool. When the causative variant has been identified in the proband, family members can undergo targeted genetic testing for that variant. Thorough genetic counseling before testing is essential; in particular, incomplete penetrance must be explained and the psychological and social implications of a positive result discussed. When the causative variant is unclear, an ALS-related multigene panel or whole-exome/whole-genome analysis (WES/WGS) is performed. General population screening for FALS is not currently recommended. A follow-up protocol for asymptomatic variant carriers has not been established, but in some clinical trials serial measurement of a biomarker (plasma neurofilament light chain, NfL) is being explored as an indicator of early neurodegeneration. Preimplantation genetic testing (PGT-M) is used to select healthy embryos in couples with an identified variant. Recently, with the expansion of tofersen clinical trials, studies are under way exploring initiation of presymptomatic treatment in SOD1 variant carriers.
FALS is diagnosed through an integrated approach of clinical evaluation, electrophysiological testing and genetic testing. The revised El Escorial criteria (Airlie House criteria) or the Gold Coast criteria (2020) are used as clinical diagnostic criteria. The Gold Coast criteria define clinically definite ALS as the coexistence of upper and lower motor neuron signs in the same body region, or a progressively spreading pure lower motor neuron syndrome. Nerve conduction studies (NCS) and electromyography (EMG) are essential to confirm lower motor neuron involvement and for differential diagnosis. Fibrillation potentials, positive sharp waves, giant motor unit potentials and reduced motor unit recruitment are characteristic, and it is important to confirm denervation findings in widespread body regions (cervical, thoracic, lumbosacral, bulbar). On blood testing, elevated plasma NfL (neurofilament light chain) is a sensitive biomarker of neurodegeneration and is used for diagnosis and monitoring of progression. Brain and spinal cord MRI may show findings suggestive of corticospinal tract degeneration (T2 hyperintensity), but sensitivity is low. Genetic testing is performed with an ALS-related multigene panel (including the C9orf72 repeat expansion), and if positive the case is classified as FALS. In the differential diagnosis, Kennedy disease, multifocal motor neuropathy, cervical myelopathy, Hirayama disease and others must be excluded.
Treatment of FALS is divided into disease-modifying therapy and supportive care. Among disease-modifying therapies, riluzole (Rilutek) is the standard therapy, blocking glutamate toxicity and extending survival by about 2–3 months. Edaravone (Radicava) is a drug that suppresses oxidative stress and has been shown to slow the rate of functional decline in some patients. Tofersen (Qalsody), approved by the FDA in 2023, is an antisense oligonucleotide specific for SOD1-ALS; when administered intrathecally, it suppresses SOD1 protein production, significantly reducing plasma NfL and mitigating functional decline. In a German multicenter study, 74% of SOD1-ALS patients were switched to tofersen treatment. ASO therapies targeting C9orf72-associated FALS are in clinical trials. Supportive care is led by a multidisciplinary team (neurology, pulmonology, rehabilitation medicine, nutrition, palliative care, speech therapy, social work) and includes noninvasive ventilation (NIV, BiPAP), cough assist devices (MI-E), percutaneous endoscopic gastrostomy (PEG), assistive devices (walking aids, power wheelchairs, communication aids), and palliative and hospice care. Mexiletine is used for muscle cramps, and amitriptyline or glycopyrrolate for excessive salivation.
FALS is a fatal disease that progressively worsens over months to years after diagnosis, and without treatment the mean survival after diagnosis is about 2–5 years. Factors affecting prognosis include site of onset (bulbar onset worse than limb onset), age of onset (younger onset somewhat better), causative gene variant (SOD1 A4V very poor; D90A relatively favorable), FVC level at diagnosis and initial NfL value. C9orf72-associated FALS has a worse prognosis due to cognitive decline when FTD is present. Respiratory failure is the main cause of death, and early application of noninvasive ventilation can significantly extend survival. With the introduction of gene-specific therapies such as tofersen, a slower rate of functional decline and reduced NfL have been confirmed in SOD1-ALS patients, but long-term data on survival benefit are still accumulating. The hypothesis that early treatment initiation in presymptomatic variant carriers can improve prognosis is being tested in clinical trials. Respiratory support, nutritional management and psychosocial support to maintain quality of life contribute greatly to the overall prognosis.
Because FALS is a monogenic disease, primary prevention through genetic counseling and reproductive choices is possible in families in which the causative variant has been identified. Preimplantation genetic testing (PGT-M) is performed together with in vitro fertilization to select and transfer embryos that do not carry the variant. Prenatal genetic diagnosis (amniocentesis or chorionic villus sampling) can determine whether the fetus carries the variant. Asymptomatic adults who undergo predictive genetic testing and learn that they are variant-positive should receive thorough genetic counseling and psychological support, and there is some evidence that lifestyle management (regular exercise, minimizing exposure to toxic substances, preventing head trauma) may help reduce the risk of onset. Participation in clinical trials explores the effect of early intervention in presymptomatic variant carriers while also providing the benefit of medical monitoring. In terms of secondary prevention, it is important to diagnose early at the onset of symptoms and promptly start riluzole, edaravone and tofersen to slow the rate of functional decline. Smoking, excessive drinking and extreme physical stress have been proposed as risk factors for ALS, so preventive lifestyle improvement is recommended.